Grace Therapeutics, Inc. Net Income Loss

• Grace Therapeutics, Inc. showed an increase of +25.6% in Net Income Loss from 2024 to 2025.
• This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Grace Therapeutics, Inc.'s Net Income Loss has grown by 75.7%.
• Historical annual values: Fiscal year 2025: -$9.57 million | Fiscal year 2024: -$12.85 million | Fiscal year 2023: -$42.43 million | Fiscal year 2022: -$9.82 million | Fiscal year 2021: -$19.68 million | Fiscal year 2020: -$25.51 million | Fiscal year 2019: -$39.37 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026